Scalper1 News
Specialty drugmaker Mallinckrodt (MNK) said Thursday that the FDA is no longer recognizing its generic ADHD drug as equivalent to the original, which would essentially knock it out of the market. Mallinckrodt was down 5.5% in morning trading in the stock market today, near 88. Malinckrodt stock touched an all-time high near 96 on Nov. 5. The drug in question, methylphenidate ER, is a generic version of Concerta, Johnson & Johnson’s (JNJ) Scalper1 News
Scalper1 News